The company’s presence at the October trade event underscored a deliberate pivot toward deep local integration. Beyond existing sales in the UK and EU, Kexing is formalizing its footprint through a German subsidiary, with active plans to establish direct operations in France, Italy, Spain, and the Netherlands. This regional infrastructure aims to tighten supply chains and strengthen direct engagement with local biotech purchasers.

Kexing’s current commercial engine relies on a network spanning roughly 70 countries, supported by nearly 200 active international registration applications. Its pipeline now features over 10 high-value biosimilars, with a strategic focus on chronic conditions including inflammatory bowel disease, systemic lupus erythematosus, and cancer cachexia. By leveraging three decades of industrial-scale manufacturing experience, the company intends to scale these assets to meet specific clinical gaps identified across international markets.